Alzheimer’s & Dementia

Filter Your Results




First Participant Dosed in Phase 2 Trial of Phosphodiesterase Inhibitor AR1001 for Alzheimer’s Disease

Friday, April 12, 2019—The first patient has been dosed in a phase 2 study evaluating safety and efficacy of AR1001 (AR1001; AriBio, San Diego, CA). A novel phosphodiesterase inhibitor, AR1001, is b…

Technology Has Potential to Halt Production of Mutated Protein in Huntington’s Disease and Spinocerebellar Ataxia

Monday, April 08, 2019—Early data supports a potential therapy for neurodegenerative diseases such as Huntington’s disease (HD) and spinocerebellar ataxia (SCA) that are caused by trinucleotid…

First Patients Dosed in Trial of Two-Drug Combination Therapy for Alzheimer’s Disease

Thursday, April 04, 2019—The first patients were dosed in a Phase 2 clinical trial to assess AMX0035 (Amylyx Pharmaceuticals, Inc., Cambridge, MA) in patients with Alzheimer’s disease. AMX0035 i…

Combination Drug Shows Promise for Treating Alzheimer’s-Associated Agitation

Friday, March 29, 2019—A combination of deudextromethorphan hydrobromide and quinidine sulfate (AVP-786; Avanir Pharmaceuticals, Alisa Viejo, CA) is being studied as potential treatment of moderate-…

Trofinetide Phase 2 Study Shows Safety and Clinically Relevant Improvement for Rett’s Syndrome

Wednesday, March 27, 2019—Positive results from a phase 2 randomized, placebo-controlled clinical trial (NCT02715115) of trofinetide (Acadia Pharmaceuticals, San Diego, CA; Neuren Pharmaceuticals, Melb…

FDA Finds Transcranial Magnetic Stimulation Plus Cognitive Training Exercise Safe, But Not Effective for Alzheimer's Disease

Tuesday, March 26, 2019—The Food and Drug Administration (FDA) Neurologic Devices Advisory Panel voted unanimously (14-0) not to recommend approval of transcranial magnetic stimulation (TMS) plus cog…

First Participant Treated with Proprietary Plasma Fraction in Phase 2 Trial for Severe Alzheimer’s Disease

Monday, March 25, 2019—In a phase 2 clinical trial (NCT03765762), the first participant has received a dose of the proprietary plasma fraction (PPF)(GRF6019) developed by Alkahest (San Carlos, CA) i…

Phase 3 Open Label Extension Study for BAN 2401 for Mild Cognitive Impairment Launches

Friday, March 08, 2019—A phase 3 study to investigate a humanized monoclonal antibody as a potential therapy for mild cognitive impairment from Alzheimer’s disease (AD)began this month. T…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.